HC Wainwright set a $9.00 price target on Evoke Pharma (NASDAQ:EVOK) in a report published on Wednesday. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.

Several other equities research analysts also recently commented on EVOK. Zacks Investment Research downgraded Evoke Pharma from a hold rating to a sell rating in a report on Thursday, August 17th. ValuEngine raised Evoke Pharma from a sell rating to a hold rating in a report on Saturday, August 26th. Seaport Global Securities reissued a buy rating and issued a $10.00 target price on shares of Evoke Pharma in a report on Friday, October 6th. Northland Securities reissued a buy rating and issued a $10.00 target price on shares of Evoke Pharma in a report on Wednesday, October 18th. Finally, FBR & Co reissued a buy rating and issued a $10.00 target price on shares of Evoke Pharma in a report on Thursday, October 19th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average target price of $9.00.

Evoke Pharma (EVOK) remained flat at $$2.67 during midday trading on Wednesday. 27,243 shares of the company traded hands, compared to its average volume of 350,959. Evoke Pharma has a 52-week low of $1.42 and a 52-week high of $4.55.

Evoke Pharma (NASDAQ:EVOK) last released its quarterly earnings results on Tuesday, November 14th. The specialty pharmaceutical company reported ($0.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.13). During the same quarter in the prior year, the company posted ($0.29) earnings per share. equities analysts forecast that Evoke Pharma will post -1 EPS for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the business. Sphera Funds Management LTD. lifted its holdings in shares of Evoke Pharma by 14.2% during the third quarter. Sphera Funds Management LTD. now owns 571,022 shares of the specialty pharmaceutical company’s stock valued at $1,907,000 after purchasing an additional 71,022 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Evoke Pharma by 15.1% during the second quarter. Vanguard Group Inc. now owns 523,650 shares of the specialty pharmaceutical company’s stock valued at $1,341,000 after purchasing an additional 68,544 shares in the last quarter. Finally, State Treasurer State of Michigan lifted its holdings in shares of Evoke Pharma by 37.0% during the second quarter. State Treasurer State of Michigan now owns 400,000 shares of the specialty pharmaceutical company’s stock valued at $1,024,000 after purchasing an additional 108,034 shares in the last quarter. 13.64% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This piece was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://www.thecerbatgem.com/2017/12/02/hc-wainwright-analysts-give-evoke-pharma-evok-a-9-00-price-target.html.

About Evoke Pharma

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Analyst Recommendations for Evoke Pharma (NASDAQ:EVOK)

Receive News & Stock Ratings for Evoke Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma Inc. and related stocks with our FREE daily email newsletter.